Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 309.00
Ask: 310.00
Change: 10.00 (3.33%)
Spread: 1.00 (0.324%)
Open: 304.00
High: 316.00
Low: 304.00
Prev. Close: 300.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Tue, 09th Jun 2020 13:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Venture Life Group PLC - Berkshire-based self care products maker - Says order book "significantly ahead" of year prior. Reports solid demand for hand sanitiser gel product. Extends relationship with Alliance Pharma, becoming second manufacturer of Wiltshire-based pharmaceutical firm's Kelo-Cote scar gel products.

----------

Better Capital PCC Ltd - Guernsey-based investment company - To take write-down on valuation of investment in Everest, a British windows and home improvement firm. Better Capital's Fund II has invested GBP3.2 million into creation of Everest 2020, which bought assets of Everest Ltd, including its order pipeline. Pre-packaged administration deal rescued over 400 jobs at Everest and ensures existing orders can be completed.

----------

Plaza Centers NV - Netherlands-based property firm - Says buyer of company's stake in a shopping and entertainment centre in Belgrade will pay firm EUR830,000 to settle purchase. Plaza Centers to increase amount paid to bondholders to EUR500,000 from EUR250,000 at next payment date on July 1.

----------

Altyn PLC - gold miner in Kazakhstan - Says "positive momentum" continuing in second quarter with annualised monthly production run rate of 600,000 tonnes per year achieved in April and May. Altyn adds this represents 60% growth quarter-on-quarter. Altyn explains gold recovery grades also improved and beating budgeted targets. Seeing pick up in interest among investors, so far raised USD3.2 million out of USD10 million maximum in Astana Stock Exchange bond issue.

----------

Ormonde Mining PLC - Spain-focused natural resources - Cost-effective work programme at existing Spanish gold assets being advanced. Continuing to assess prospective projects, with 100 reviewed to date and a handful shortlisted "for further active consideration".

----------

Chaarat Gold Holdings Ltd - Gold miner in Armenia and Kyrgyz Republic - Targets 300,000 ounces per year production from 2026 at Kyzyltash deposit, Kyrgyz Republic. Lays out plans to get there, beginning with updated feasibility study in 2022, project financing in 2023 before construction follows in 2024 and 2025.

----------

Rockfire Resources PLC - Australia-focused gold and copper explorer - Reports results of 3D magnetic imagery at Plateau gold deposit in Lighthouse tenements, Australia. Probe confirms gold target beyond a depth of 600 metres. Field crew now in place to prepare for start of drilling.

----------

Star Phoenix Group Ltd - oilfield services firm in Trinidad - Yet to receive outstanding USD1.5 million payment from LandOcean Energy Services Co Ltd over sale of Range Resources Trinidad Ltd. Agreed deadline for payment was Monday and Star Phoenix has made "numerous attempts" to secure cash. Company now working with legal advisers.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Awarded grant for research with Cardiff University to assess whether its DPD‑207, XF-70 and XF-73 drug compounds can treat fungal infections. Financial terms of partnership not disclosed.

----------

PureTech Health PLC - biotherapeutics firm based in Massachusetts - Reports "positive" data from founding company Vedanta Biosciences Inc's two Phase 1 studies of VE202 candidate for inflammatory bowel disease. Study shows VE202 was "safe and well-tolerated at all doses".

----------

Hutchison China Meditech Ltd - Hong Kong-based biopharmaceutical firm - Enters into agreement with Guangzhou government for planned return of Hutchison's remaining 34 years land-use rights of about 30,000 square meters of unused site. Hutchison will secure USD95 million for the return of the site.

----------

iEnergizer Ltd - Guernsey-based IT services firm - Reports strong performance in six months to March 31, its year end date. Says focus remained on high margin work and revenue set to be in line with market expectations but earnings before interest, taxes, depreciation and amortisation beating forecasts. Reaffirms commitment for progressive dividend policy.

----------

Redcentric PLC - London-based IT services provider - Extends loan facilities until June 30, 2022. Extended loan is a GBP17.5 million revolving credit facility provided by Barclays Bank PLC and National Westminster Bank PLC.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
24 Mar 2021 16:44

TRADING UPDATES: Arden Partners to return to annual profitability

TRADING UPDATES: Arden Partners to return to annual profitability

Read more
4 Mar 2021 12:46

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Read more
25 Feb 2021 16:19

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
11 Jan 2021 14:51

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Read more
30 Dec 2020 22:05

IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light

IN BRIEF: Hutchison China Lands "Milestone" China Drug Green Light

Read more
29 Dec 2020 12:31

Hutchison China Files US FDA Drug Application For Cancer Treatment

Hutchison China Files US FDA Drug Application For Cancer Treatment

Read more
17 Nov 2020 19:31

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

IN BRIEF: Hutchison Chi-Med To Issue USD100 Million In Shares To CPP

Read more
17 Sep 2020 21:35

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

Read more
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.